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1  |  INTRODUC TION
Cerebrovascular diseases include a number of conditions that involve 
thrombosis and inflammation, including stroke, intracranial stenosis, 
aneurysms, carotid and vertebral stenosis, and vascular malforma-
tions. Ischemic stroke is one of the leading causes of morbidity and 
mortality worldwide, and the leading cause of adult disability, re-
sulting in a significant socioeconomic burden.1,2 Rapid recanalization 
with intravenous thrombolysis or endovascular thrombectomy is the 
mainstay of current and evolving acute ischemic stroke manage-
ment.3 However, there is limited indication of rapid recanalization 
therapies due to a shorter time window and availability of stroke 
centers, and a large number of patients with ischemic stroke re-
ceive no acute therapy resulting in significant residual neurological 
damage, a long- term recovery period, and further risk of recurrent 
events and complications.4 Therefore, there is a rapidly growing clin-
ical need of additional therapies which may not be time- sensitive 
and can be given to a wider number of stroke patients and in non- 
specialty centers. In recent years, there has been a considerable 
advancement in the research and development of neuroprotective 
and anti- inflammatory agents as potential adjunctive therapies in 
both pre- clinical clinical models.5,6 In our own work, we have shown 
that pharmacologically targeting the Annexin A1/formyl peptide re-
ceptor (FPR)- 2 pathway can significantly attenuate cerebrovascular 
thrombo- inflammation by modifying neutrophil- platelet phenotype 
from pro- inflammatory to pro- resolutory.7,8
The cerebral microcirculation (comprising of neurovasculature 
within the brain <100 μm in diameter) is the most critical part of neuro-
vascular bed, providing all metabolic needs to the cerebral parenchyma. 
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Abstract
The intertwined processes of thrombosis and inflammation (termed “thrombo- 
inflammation”) are significant drivers of cerebrovascular diseases, and as such, they 
represent prime targets for drug discovery programs focusing on treatment and 
management of cerebrovascular diseases. Most cerebrovascular events result from 
chronic systemic microcirculatory dysfunction due to underlying conditions, for exam-
ple, hypertension, diabetes mellitus, coronary artery disease, dyslipidemia, and sickle 
cell disease. Immune cells especially neutrophils play a critical role in the onset and 
maintenance of neuroinflammatory responses in the microcirculation. Neutrophils 
have the ability to drive both inflammatory and anti- inflammatory/pro- resolution 
effects depending on the underlying vascular state (physiological vs. pathological). 
In this article, we highlight the pathophysiological role of neutrophils in stroke and 
discuss ongoing pharmacotherapeutic strategies that are focused on identifying po-
tential therapeutic targets for enhancing neuroprotection, mitigating inflammatory 
pathways, and enabling resolution.
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Therefore, cerebral microvascular dysfunction plays a significant role in 
the setting of common neurovascular abnormalities, with thrombosis 
and inflammation working in a concerted fashion. Consequently, under-
standing the relationship between thrombosis and inflammation, that is, 
“thrombo- inflammation,” in the cerebral microcirculation is critical in de-
vising therapeutic strategies that can aggressively target and resolve any 
evolving cerebral thrombotic events such as ischemic stroke (Figure 1).9
1.1  |  Stroke
Stroke is one of the leading causes of death and long- term disability 
worldwide. In the United States alone, almost 800,000 stroke- related 
events occur each year.2 In the majority of cases, stroke is the result 
of multiple underlying risk factors including hypertension, obstructive 
sleep apnea, dyslipidemia, atrial fibrillation, and genetic disorders, for ex-
ample, sickle cell disease (SCD).10- 14 There are two main types of stroke: 
acute ischemic or hemorrhagic stroke, with the former bringing ten times 
more prevalent than the latter, but the latter having worse prognosis.15 
Acute ischemic stroke is further classified into etiologic subtypes such as 
cardioembolic, atherosclerotic, lacunar, cryptogenic, and unusual cases 
(eg, vasculitis, dissection, drug abuse, SCD, Alzheimer's disease).16 The 
type of stroke suffered is dependent upon several factors including dif-
ferent populations, underlying risk factors, and events leading up to the 
stroke itself. Most of the stroke- related pre- clinical and clinical work is 
focused on the related pathophysiology, including the involvement of 
the neurovascular unit and blood- borne cells, for example, neutrophils.17
1.2  |  Brain microvascular endothelial cells and 
cerebral blood flow in stroke
Brain microvascular endothelial cells are a central part of the neuro-
vascular unit (formed by neurones, interneurons, astrocytes, basal 
F I G U R E  1 Role	of	thrombo-	inflammation	in	cerebral	microcirculatory	dysfunction	I.	Initiation:	Under	thrombo-	inflammatory	conditions,	
there is increased pathophysiological infiltration of circulating leukocytes (including neutrophils) and platelets into the brain through the 
BBB. II. Activation and propagation: The severe recruitment of neutrophils at the inflammatory site results in increased expression of 
adhesion molecules such as L- selectin, P- selectin, and intracellular adhesion molecule- 1, on microvascular brain endothelial cells (MBECs). 
Additionally, neutrophils activated at the site of neuro- inflammation express various mediators including neutrophil extracellular traps (NETs) 
and reactive oxygen species (ROS). NETs are laced with pro- coagulant/pro- thrombotic factors such as citrullinated histone (H3Cit), cathepsin 
G, and neutrophil elastase (NE) which interact with platelets resulting in platelet activation and aggregation. Activated platelets in itself 
cause further NET production from neutrophils in a vicious cycle. III. Microvascular Occlusion: This persistent response eventually leads to 
activation of coagulation cascade culminating in fibrin formation and clot development (thrombus). Within the cerebral microvasculature, 
neural activity can itself regulate neurovascular flow and activation by releasing neurotransmitters, cytokines, including angiogenesis 
mediators. In response to cerebral ischemia, microglia produce variety of pro- inflammatory cytokines (eg, interleukin [IL]- 1, IL- 6, tumor 
necrosis factor- alpha, ROS, and proteolytic enzymes), which further escalates the pro- thrombo- inflammatory phenotype
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lamina covered with smooth muscular cells and pericytes, endothe-
lial cells, and extracellular matrix) and the associated blood- brain 
barrier (BBB) structures (including tight junctions, basal lamina, 
pericytes, and parenchymal cells including astrocytes, neurons, and 
interneurons).18 This complex neurovasculature regulates cerebral 
blood flow and nutrient delivery via a wide range of transport mech-
anisms. In contrast to peripheral endothelial cells, brain microvascu-
lar endothelial cells express specific ion transporters and receptors, 
and contain fewer fenestrations and pinocytotic vesicles, which 
makes cerebral blood vessels a highly selective molecular transport 
process, thereby maintaining cerebral homeostasis.19,20 Much cer-
ebral blood flow regulation is also attained by autoregulation which 
ensures adequate delivery of oxygen and nutrients through changes 
in the cerebral vascular tone.21,22
The BBB makes the central nervous system (CNS) an immuno-
logically privileged center.18 Additionally, the absence of traditional 
lymphatics, lack of major histocompatibility complex class II– 
expressing antigen- presenting cells, metabolic demands, and other 
factors contribute to CNS sterilization.18 Thus, under a normal phys-
iological state there is less communication between the peripheral 
immune system and the CNS. However, during the setting of acute 
cerebrovascular events (eg, ischemic stroke), thrombo- inflammatory 
pathways become activated resulting in pathophysiological infiltra-
tion of circulating leukocytes (including neutrophils, monocytes, and 
lymphocytes) into the brain through the BBB. Neuroinflammatory 
responses are further orchestrated by the production of cytokines 
from infiltrated leukocytes within the brain, increased expression of 
the adhesion molecules on the cerebral endothelium, followed by 
further migration and recruitment of the leukocytes across the en-
dothelium.20,23 Neural activity in itself can control the neurovascula-
ture by releasing neurotransmitters (mainly glutamate excitotoxicity 
from neurons and glial cells)24 and growth factors (vascular endo-
thelial growth factor) further amplifying cerebrovascular patterning 
based on the pathophysiological milieu (Figure 1).25,26
1.3  |  Cerebral microcirculation and thrombo- 
inflammation
The microcirculation is the terminal vascular network of the sys-
temic circulation. Recent studies have given a clearer understand-
ing of cerebral microcirculatory circuits and flow mainly involving 
leukocytes, platelets, and erythrocytes and their interaction with 
brain microvascular endothelial cells.9,18 Leukocytes (in particular 
neutrophils) are the most abundant and the first line of defensive 
cells to be recruited (within minutes), transported and transmigrated 
through the endothelium.9 Neutrophils have been classified as the 
main armor of the innate immune system with diverse functions 
in both acute and chronic inflammatory responses.27 Neutrophils 
enable thrombo- inflammation, by their ability to express various 
pro- thrombotic/pro- inflammatory mediators such as neutrophil 
extracellular traps (NETs), reactive oxygen species (ROS), and neu-
trophil serine proteases which can all independently, or collectively, 
upregulate thrombo- inflammatory processes.7,8,28- 31 Neutrophils 
are rarely found in the brain parenchyma under a physiological set-
ting, due to the presence of the BBB, and are only sparsely seen in 
cerebral spinal fluid, meninges, and pia mater where they provide 
immune surveillance.32 However, during neurovascular insults, such 
as ischemic stroke or traumatic brain injury, there is a huge influx of 
neutrophils which can significantly influence and impede normal mi-
crocirculatory rheology along the affected neurovascular sites.32,33 
These interactions have been shown to lead to an increase in se-
lectins (eg, P- and E- selectin) and adhesion molecule (eg, intracel-
lular adhesion molecule- 1) expression on murine brain endothelial 
cells hindering vascular flow and predisposing the brain to the vaso- 
occlusive phenomena.34 The initial neutrophil response also leads to 
interactions with platelets via a variety of different mechanisms such 
as Mac- 1 (CD11b/CD18)/glycoprotein Ib (CD42) and P- Selectin/P- 
selectin glycoprotein ligand- 1, formation of fibrin cross- links (via 
Mac- 1/fibrin interaction), and induction of extrinsic Tissue factor/
factor IIa pathway, generating thrombin.30 These neutrophil- platelet 
aggregates have been associated with stroke progression, but it is 
still unclear as to whether the direct interaction between platelets 
and neutrophils is critical for the pathogenesis of ischemic stroke, 
although evidence suggests they are heavily involved.
1.4  |  Neutrophil cross- talk in stroke
Neutrophils are one of the earliest players of stroke pathogenesis, 
interacting with platelets, microvascular brain endothelial cells, 
microglial cells, and the cerebral microvessels.35 Blood- borne neu-
trophils can migrate within few minutes of ictus (stroke onset) with 
the zenith achieved between 48 and 72 h after the ischemic stroke 
event.36 The interaction of activated neutrophils with surrounding 
vascular milieu actively promotes BBB disruption, collagen deg-
radation, and hemorrhagic transformation through the release of 
proteases such as matrix metalloproteases, neutrophil serine pro-
teinases (eg, neutrophil elastase, cathepsin G, and proteinase 3), and 
ROS. Neutrophil- dependent ROS can further disrupt neurovascular 
architecture in stroke through modification of microvascular brain 
endothelial cells, pericytes, astrocytes, and neurons.36 This rich 
thrombo- inflammatory milieu results in further platelet aggregation 
and coagulation, aided by the production of NETs and contributing 
to secondary thrombotic events.28,37 Presence of citrullinated his-
tone H3 which is characteristic of NETs, in thrombi, is known to be 
associated with adverse stroke prognosis and usually secondary to 
cardioembolic etiology (Figure 1).38
1.5  |  Neutrophil- platelet interactions in cerebral 
thrombo- inflammation
Compelling evidence from in vivo animal models and in vitro human 
studies has demonstrated neutrophils work intimately with platelets 
via three distinct mechanisms to promote thrombo- inflammation: 
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(1) The first mechanism involves the production of NETs, which are 
composed of DNA filaments laced with histones, proteases, and 
granular and cytosolic proteins (all of which are known to be pro- 
thrombotic in nature).39 In vitro and in vivo models have been used 
to provide compelling evidence demonstrating the abundance of 
pathological NETs in stroke thrombi, including clots obtained from 
ischemic stroke patients.40,41 The pro- thrombotic nature of NETs 
has been attributed to the presence of citrullinated histone pro-
teins, neutrophil elastase, and cathepsin G.42,43 Furthermore, NETs 
are decorated with phosphatidylserine which provides functional 
platforms for platelet microparticles and coagulation factor deposi-
tion, aiding thrombogenesis.41 (2) The second mechanism involves 
neutrophil serine proteases which can regulate pro- thrombotic 
and pro- inflammatory responses by interacting with platelets and 
coagulation factors28 and binding with, for example, FPRs on neu-
trophils and monocytes.44,45 Cathepsin G and neutrophil elastase 
are the most common neutrophil serine proteases and can induce 
a pro- thrombotic environment by stimulating platelet aggregation 
and activating the coagulation cascade.28 Cathepsin G may also be 
producing some of these effects by interacting with FPRs44 or its 
agonists such as Annexin A1.45 (3) Finally, the third mechanism in-
volves tissue factor, a cell- surface, integral- membrane protein, and 
the initiator of the extrinsic pathway. Neutrophils can passively 
acquire tissue factor from activated monocytes, transferring it to 
platelets during thrombus formation via tissue factor containing 
microparticles.46,47
1.6  |  The role of resolution biology in thrombo- 
inflammation
There is a growing evidence of the importance of resolution biol-
ogy in vascular inflammation. Classic resolution is defined as the 
“period between peak inflammatory cell influx and the clearance of 
immune cells from the site of tissue injury and the restoration of 
functional homeostasis.” It involves a tightly regulated engagement 
of specialized lipid mediators (eg, resolvins, lipoxins, maresins, pro-
tectins) and resolver proteins (eg, Annexin 1 and Annexin 1- derived 
peptides),7,48- 53 which are actively involved in the recovery phase 
of inflammation in acute and chronic conditions.49,54- 57 Annexin 1 
holds a special position in the resolution family of mediators due to 
the ability of the parent protein and its mimetic peptides to act as a 
pivotal homeostatic mediator targeting both endogenous inflamma-
tory and pro- resolving pathways, and in so doing is associated with a 
lower degree of secondary effects. Our own studies have shown that 
Annexin A1 and its mimetic peptide (Ac2- 26) afford cerebrovascular 
protection against ischemic stroke by modifying both neutrophil and 
platelet phenotypes by engaging endogenous pro- resolving, anti- 
thrombo- inflammatory circuits.7,8 A number of other studies have 
demonstrated an alteration or dysregulation of resolution biology 
in a mixture of inflammatory conditions including, but not limited to, 
cerebrovascular diseases, neurodegenerative conditions, metabolic 
syndromes, and autoimmune diseases.7,58- 62
More recently, the field has coined a third resolution phase (the 
first two being inflammation and resolution) in which the affected 
tissue develops adaptive immunity (whereby innate and adaptive 
immunity is bridged by the production of local pro- resolution pro-
cesses, as well as tissue reprogramming).54 This third phase is termed 
“post- resolution,” and currently evidence suggests that in certain 
situations, “frustrated resolution” may occur in which adaptive im-
munity is not fully achieved.63 Further work is needed in order to 
continue to develop and expand pharmacological strategies involv-
ing resolution biology, for example, in maladaptive immunity, are 
the roles and mechanisms used by neutrophils and other leukocyte 
subtypes parallel those in acute inflammation, or is there a shift in 
immune function?
1.7  |  SCD and thrombo- inflammation
Sickle cell disease is a hereditary hemoglobin defect associated with 
early- onset cerebrovascular events including acute ischemic strokes, 
silent cerebral infarcts, moyamoya disease, and intracerebral hemor-
rhages.64 Sickle hemoglobin polymerizes, causing structural damage 
and altering the erythrocyte membrane. These effects result in ex-
cessive hemolysis which activates the vascular milieu via production 
of heme microparticles and arginase into the plasma. This persistent, 
cyclical, and chronic process results in unresolved inflammation,53 
and leukocytes (especially SCD neutrophils) have been associated 
with the pathogenesis of SCD.65- 67 Neutrophilia in SCD is considered 
a significant risk factor for evolution of cerebrovascular diseases,64 
and SCD neutrophils are hyperinflammatory particularly during 
the vaso- occlusive crisis.68 SCD neutrophils stimulate surrounding 
platelets and endothelium, therefore activating coagulation cascade. 
Additionally, heme released from lysed red blood cells activates neu-
trophils to produce NETs that may bind with sickled red blood cells 
and platelets, further provoking thrombus formation within the cer-
ebral microvessels.69 Interestingly, as with other chronic inflamma-
tory conditions, SCD has been known to be associated with impaired 
resolution process resulting in excessive uncontrolled inflamma-
tion.53 Our work (Ansari et al.) will further highlight the importance 
of pathological neutrophil function and hampered resolution biology 
in SCD cerebral phenotype and how exogenous Annexin A1 mimetic 
peptide Ac2- 26 can mitigate neutrophil- dependent thrombo- 
inflammatory responses and attenuate thrombosis in SCD.70
1.8  |  History and current treatment options for 
acute ischemic stroke patients
Prompt reperfusion is the cornerstone of acute ischemic stroke 
patient management. Recanalization with intravenous thromboly-
sis with tissue plasminogen activator (tPA) or endovascular treat-
ment in combination with intravenous thrombolysis is the mainstay 
of acute ischemic stroke management. Despite these approaches, 
there has been a historic gap between evolution of therapies for 
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stroke vs. myocardial infarction.71 Intravenous thrombolysis with 
tPA has been the most important breakthrough treatment for is-
chemic stroke since the Food and Drug Administration approval 
in 1996 based on multiple studies showing significant clinical out-
comes.72 Subsequent studies have emphasized the rapid treatment 
and favorable outcomes with as much as up to 4.5 h after the onset 
of ischemic stroke, although with a risk of intracranial hemorrhage 
in some patients.73 Recent work has suggested superiority in treat-
ment with a new clot buster “tenecteplase” (TNK). TNK is a vari-
ant of alteplase (tPA), but possesses greater fibrin specificity and a 
longer half- life, making it potentially safer and a more effective drug 
for stroke. It is highly likely that TNK will be the standard of care in 
the near future with higher rates of recanalization and reperfusion 
coupled with ease of intravenous administration.74 There are also 
ongoing research and clinical trials on the combination of tPA with 
other treatment modalities such as hypothermia, eptifibatide, and 
activated protein C.75- 77
One of the most common adverse outcomes of recanalization 
therapy is reperfusion injury which in some patients results in life- 
threatening complications such as hemorrhagic transformation (for 
which there is a tenfold increased risk after tPA administration).36 
Ischemia- reperfusion injury is a well- known phenomenon observed 
with microcirculatory dysfunction in almost all cerebrovascular ab-
normalities and mainly consists of two fundamental processes: the 
initial ischemic insult and the subsequent revascularization with 
enhanced activation of both innate and adaptive immune systems 
and cell death programs.78 Initial tissue hypoxia and production of 
ROS activate innate and adaptive immune systems, and both leu-
kocytes (mainly neutrophils) and platelets have been observed and 
quantified in post- ischemic cerebral microvessels. Interestingly, 
increased neutrophil counts at the time of reperfusion with tPA 
are known to be associated with increased risk of hemorrhagic 
transformation (incidence ranging from 8.5% to 40%)79 and high 
neutrophil- to- lymphocyte ratio is predictive of hemorrhagic trans-
formation in acute ischemic stroke patients.79 Thus, targeting neu-
trophils at ischemic stroke onset may mitigate reperfusion- related 
complications.80,81
Endovascular treatment approaches such as mechanical throm-
bectomy have rapidly changed the overall management strategy and 
prognosis of AIS, with substantial improvement in functional neu-
rological outcomes. Additionally, the mechanical thrombectomy has 
longer window period with up to 24 h if evidence of sizable isch-
emic penumbra.82 There is also evidence of benefit of collateral flow 
augmentation and hemodynamic regulation during proximal vessel 
acute ischemic stroke.83
Secondary stroke prevention is the most important risk- reducing 
strategy for management of strokes. The major modifiable risk fac-
tors include hypertension, diabetes mellitus, smoking, dyslipidemia, 
and physical inactivity. Two additional mechanisms that are amena-
ble to secondary prevention include atrial fibrillation and carotid ar-
tery stenosis. The risk of stroke is particularly increased if there is 
presence of two or more risk factors.3,84 The current guidelines for 
secondary stroke prevention include blood pressure control, use of 
anti- thrombotics (such as aspirin and clopidogrel), statin therapy (eg, 
atorvastatin), and lifestyle modification including smoking cessation. 
Some patients with symptomatic carotid artery stenosis may benefit 
from revascularization, and atrial fibrillation with long- term antico-
agulation85 or left atrial appendage closure devices.86
1.9  |  Evolving therapeutics and diagnostics 
for targeting the vascular inflammation and 
microcirculatory factors for the management and 
prevention of stroke
The management of cerebrovascular diseases has undergone a 
significant progress in last two decades due to research and drug 
discovery programs with the production of various systemic and 
local thrombolytic (both medical and mechanical) and neuropro-
tective strategies.87 Furthermore, there has been considerable 
advancement of high- resolution imaging techniques (including 
computed tomography, magnetic resonance imaging, and func-
tional magnetic resonance imaging) and their tracers, resulting in 
accurate assessment of core- penumbra volumes and more rapid 
and appropriate therapy with less complications.88 In our recent 
work, we created a viable fluorescent probe that has the ability to 
target and detect activated neutrophils by binding with Fpr2/ALX 
surface receptors and track inflammation.89 Development of such 
novel small molecule imaging probes will further help in detecting 
neurovascular inflammation and guide appropriate therapeutics. 
Clinical trials and designs have targeted neuro- inflammation in-
cluding decreased leukocyte recruitment, inhibiting the production 
of neutrophil- derived thrombo- inflammatory mediators and en-
hancement of anti- inflammatory/pro- resolving pathways in stroke 
(Table 1). Additional focus has been given on targeting platelets and 
endothelial cells for mitigation of ongoing inflammation. Here, we 
will focus more on the neutrophil- dependent targets and pathways 
including manipulation of resolution biology to attenuate thrombo- 
inflammation (Figure 2).
1.10  |  Targeting neutrophil- dependent thrombo- 
inflammatory mediators
Neutrophils play a major role in cerebral thrombo- inflammatory pro-
cesses by promoting thrombosis and atherosclerosis. Thrombosis in 
particular is enhanced by the release of pro- thrombotic mediators 
and direct interaction with platelets and clotting factors. Targeting 
thrombo- inflammatory mediators have an important role in pre-
venting and treating various stroke- related complications by miti-
gating inflammation and enhancing neuroprotection. As discussed 
above, all major players of thrombo- inflammation including NETs, 
neutrophil serine proteases, and ROS, when targeted have shown 
to significantly reduce stroke complications and preserve neurologi-
cal functions. Furthermore, neutrophil- derived anti- inflammatory/
pro- resolving mediators, which are known to be altered in chronic 
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inflammatory/metabolic disease, have been studied to counter 
regulate stroke pathogenesis by enabling resolution, clearance, and 
homeostasis.
A number of studies (some of which are included in Table 2, 
that focuses on emerging therapeutics targeting ischemic stroke 
pathogenesis) have shown neutrophil- derived serine proteases and 
nucleosomes contribute to cerebrovascular thrombosis by enhanc-
ing coagulation pathways. Specifically, pre- clinical models have 
shown targeting cathepsin G and neutrophil elastase can potentially 
inhibit platelet thrombus formation. Pharmacologic inhibition of 
cathepsin G improved CBF and attenuated brain injury in an animal 
stroke model.90 In a similar fashion, neutrophil elastase has shown 
TA B L E  1 Selected	clinical	trials	targeting	thrombo-	inflammatory	mediators	in	stroke
Clinical trial Phase Intervention Primary outcome Protocol no.
Combining Fingolimod with Alteplase 
Bridging with Mechanical 
Thrombectomy in Acute Ischemic 
Stroke (FAMTAIS)
2 Fingolimod Salvaged ischemic tissue index (%) NCT02956200
Efficacy and safety of FTY720 for acute 
stroke
2 Fingolimod Clinical improvement NCT02002390
Safety and efficacy of intravenous 
natalizumab in acute ischemic stroke 
(ACTION2)
2 Natalizumab Percentage of participants with 
composite global measure of 
functional disability excellent 
outcome at day 90
NCT02730455
Vinpocetine inhibits NF- κB- dependent 
inflammation in acute ischemic stroke
2,3 Vinpocetine Changes in lesion volume changes 
in lesion volume from baseline 
(DWI) to day 7 (Flair), brain 
inflammatory level, brain 
inflammatory level (MRS) 
at day 7, extent of clinical 
improvement
NCT02878772
SCIL- STROKE (subcutaneous 
interleukin−1	receptor	antagonist	in	
ischemic stroke)
2 IL−1Ra Difference in concentration of log 
(interleukin−6)	as	area	under	
the curve to day 3
NCT74236229
Minocycline to Improve Neurologic 
Outcome in Stroke (MINOS)
2 Minocycline Maximally tolerated dose of IV 
minocycline, response to 





3 Enlimomab Response to therapy at 90 days on 
the Modified Rankin Scale
Enlimomab acute stroke trial
Hu23F2G phase III stroke trial (HALT) 3 Hu23F2G Response to therapy at 90 days on 
the Modified Rankin Scale
Monoclonal antibody 
(humanized) against the 
neutrophil CD11/CD18 
cell adhesion molecule 
(Hu23F2G, LeukArrest®)
Colchicine for Prevention of Vascular 
Inflammation in Non- cardio Embolic 
Stroke (CONVINCE)
3 Colchicine Recurrence of non- fatal ischemic 
stroke, any recurrence of non- 
fatal ischemic stroke, non- fatal 
hospitalization for unstable 
angina, myocardial infarction, 
cardiac arrest, vascular death
NCT02898610
Atorvastatin in acute stroke treatment 4 Atorvastatin NIHSS at 72 h, differences in 
msRankin score
NCT02225834
Secondary prevention with HMG- CoA 
reductase inhibitor against stroke
3 Atorvastatin Incidence Rate of Stroke and TIA NCT00221104
Neuroprotection of pioglitazone in acute 
ischemic stroke
2 Pioglitazone Modified Rankin Scale (mRS) NCT02195791
Intravenous autologous bone marrow- 
derived stem cells therapy for patients 
with acute ischemic stroke
2 Bone Marrow– 
derived 
Stem Cells
Modified Barthel Index score at six- 
month post- randomization
NCT01501773





Incidence of adverse events NCT01151124
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to mount a pro- thrombotic environment with the ability of neutro-
phil elastase to colocalize and facilitate degradation of tissue factor 
pathway inhibitor.28 At present, no clinical trials are in place testing 
the effects of inhibiting serine proteases in the management of cere-
brovascular diseases.
Neutrophil extracellular traps are chromatin structures laced 
with pro- thrombotic, pro- coagulant factors and are known to sig-
nificantly contribute to venous and arterial thrombosis. A large body 
of pre- clinical work has been focused on targeting NETs to alleviate 
thrombo- inflammation. One of the earlier evidences was based on 
using PAD4 knockout mice and PAD4 inhibitors which demonstrated 
reduced thrombosis in murine model.91,92 In our own work, we have 
demonstrated the important role that neutrophils play in SCD, re-
vealing that making sickle cell mice neutropenic significantly reduce 
the thrombotic potential in the cerebral microvessels, our more 
recent findings have further reported on the mechanistic insights 
and pharmacological approaches of targeting neutrophil- dependent 
thrombo- inflammation to promote resolution.69
1.11  |  Targeting neutrophil transmigration
Under chronic inflammatory states and especially during heightened 
crisis such as uncontrolled glucose, severe hypertension, or uncon-
trolled hyperlipidemia, there is increased activation and recruitment 
of neutrophils in the cerebrovascular milieu.93 In addition, during 
acute stroke events, there is an enhanced neutrophil recruitment 
into the ipsilateral side resulting in localized inflammation, which is 
often coupled to a secondary ischemic insult of the penumbra. As 
such, preventing neutrophil recruitment, adhesion, and transmigra-
tion has been considered a viable strategy by many pre- clinical and 
clinical models.
F I G U R E  2 Schematic	depiction	of	potential	thrombo-	inflammatory	targets	in	neurovascular	inflammation.	Depiction	of	various	aspects	
of neurovascular inflammation that can be therapeutically targeted. (1) Blockade of CXCR2 can reduce neutrophil activation and migration 
to the neurovascular insult site and mitigate inflammation. (2) Targeting platelet- dependent resolution with FPR2/ALX agonists such as 
Annexin A1 has shown to significantly impede cerebral thrombo- inflammatory processes and maybe neuroprotective in ischemic events. (3) 
CD11/CD18 antagonists have shown diminished neutrophil infiltration and transmigration. (4) Targeting reactive oxygen species attenuates 
neurovascular inflammation by reducing oxidative stress, inflammation, maintaining blood- brain barrier, reducing edema formation, and 
finally enabling apoptosis and autophagy. (5) Enabling neutrophil resolution by Annexin A1 treatment can reduce neutrophil activation 
and release of pro- thrombotic mediators subsequently resulting in neutrophil apoptosis and clearance
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P- selectin and intracellular adhesion molecule- 1 are main driv-
ers to neutrophil adhesion to the MBECs and inhibiting P- selectin 
or intracellular adhesion molecule- 1– mediated neutrophil recruit-
ment has been studied as a possible anti- neutrophil adhesive strat-
egy.87,94,95 Using this hypothesis, CD18 (leukocyte counter- ligand 
to endothelial intracellular adhesion molecule- 1) knockout mice 
showed diminished neutrophil recruitment and significant neuropro-
tection in the setting of a cerebral ischemia/reperfusion.94 However, 
earlier clinical trials with anti- ICAM antibody enlimomab proved in-
effective with no improvement in functional outcome and stroke se-
verity.96 Additional studies involving anti– E- selectin, anti– L- selectin, 
and chemokine receptors had none to minimal response in animal 
models.36
1.12  |  Targeting oxidative stress
Leukocyte (especially neutrophil) recruitment to the cerebro-
vascular inflammatory sites results in overwhelming oxidative 
stress due to production of ROS. Brain resident cells such as mi-
croglia and astrocytes are the main sources of ROS within the 
CNS.97 Furthermore, during the reperfusion phase of ischemia- 
reperfusion injury, there is rapid increase in the production of 
ROS, damaging the vascular and parenchymal structures causing 
widespread damage.98 In acute ischemic stroke, ROS has been 
further implicated in the hemorrhagic transformation and cer-
ebral edema, which are both major complications of revasculari-
zation therapy.98 As with other forms of vascular inflammation, 
role of oxidative stress and therapeutically targeting ROS has 
been widely studied in neurovascular inflammatory conditions. As 
eluded by various studies, targeting ROS production attenuates 
neurovascular inflammation by reducing oxidative stress, inflam-
mation, maintaining BBB, reducing edema formation, and finally 
enabling apoptosis and autophagy.99 Remote ischemic condition-
ing (which inhibits activation of nicotinamide adenine dinucleo-
tide phosphate oxidase in neutrophils)100 and hypothermia (which 
decreases the generation of free radicals, inhibits the induction 
of oxidative DNA lesions, and suppresses immune system)101 are 
non- pharmacologic adjunctive ROS directed therapies that are 
currently being tested to enhance neurovascular protection in is-
chemic stroke. Edaravone,102 uric acid,103 and citicoline104 have 
been utilized to eliminate free radicals and have shown to mitigate 
ischemic- reperfusion injury and promote neurovascular recovery 
after stroke.98
1.13  |  Enhancing resolution of thrombo- 
inflammation
Endogenous- specialized pro- resolving mediators which enhance the 
ability of vascular milieu to clear inflammatory phase and enable ho-
meostasis have shown to be of benefit in many pre- clinical models 
of vascular inflammation.54,105,106 These mediators act on differ-
ent stages of the inflammatory cascade, restoring physiological re-
sponses by, for example, reducing neutrophil recruitment, inhibiting 
cytokine release, promoting apoptosis and phagocytosis, decreasing 
vascular permeability, regulating neutrophil- platelet complexes, and 
delaying the overall cerebral thrombotic responses.7,8,57,107,108 More 
TA B L E  2 Emerging	therapeutics	ischemic	stroke	pathogenesis
Pathophysiology Intervention Therapeutic mechanism Clinical situation Ref
Neutrophil migration CXCR2 blockade Decreased neutrophil recruitment, increased 
neutrophil apoptosis, reduced CXCR2 levels, 
inducible NOS and NOX2 expression of BM 
neutrophils
Ischemic stroke 1
Neutrophil infiltration CD11/CD18	blockade	(LFA−1) Reduced adhesivity for both quiescent and 
cytokine- activated endothelial monolayers
Ischemic stroke 2
Neutrophil resolution AnxA1 treatment Reduces infarct size and edema
Reduces neutrophil migration
Reduces leukocyte- platelet interaction, 
Restoration of BBB
Inhibits lipopolysaccharide and SCD- induced 
cerebral inflammation
Inhibits neutrophil- dependent cerebral thrombosis
Reduces H3Cit+ rich NET production
Ischemic stroke 3- 5
Platelet resolution AnxA1 treatment Reduced platelet activation and aggregate 
formation, delayed thrombosis, enhanced 
phagocytosis by neutrophils
Ischemic stroke 4
ROS inhibition ROS scavengers, NADPH 
inhibitors, iNOS inhibitors, 
XO inhibitors
Inhibition of initial and later phase ROS- induced 
inflammatory damage
Ischemic stroke 6
Abbreviations: AnxA1, Annexin A1; BBB, blood- brain barrier; CXCR2, CXC chemokine receptor 2; iNOS, inducible isoform nitric oxide synthase; 
NADPH, nicotinamide adenine dinucleotide phosphate; NETs, neutrophil extracellular traps; NOX2, NADPH oxidase 2; ROS, reactive oxygen species; 
XO, xanthine oxidase.
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specifically, in our study models, we have shown that Annexin A1 
(and its N- terminal– derived peptide) modifies neutrophil- platelet 
interaction by activating the Annexin A1/FPR- 2 pathway in both 
neutrophils and platelets, with AnxA1 administration leading to re-
duced platelet activation and aggregate formation, delayed throm-
bosis, and enhanced platelet phagocytosis by neutrophils.7,106 Some 
of these mechanisms were dependent upon AKT, intracellular Ca2+, 
and Rap1 and suggested a role for Annexin A1 to affect integrin 
(αIIbβ3) activation.
7 In addition, we also showed that aspirin- triggered 
lipoxin, a specific FPR- 2, markedly attenuated inflammatory re-
sponses, including neutrophil- platelet aggregates in a murine model 
of ischemic stroke.8
2  |  CONCLUDING REMARKS
Neutrophils play a significant role in the pathogenesis of cerebrovas-
cular abnormalities and participate in the onset and propagation of 
cerebrovascular thrombo- inflammation (especially in the context of 
ischemic stroke) in the acute and chronic setting. Neutrophils work 
in a “dichotomous” fashion and have the capacity to exhibit pro- and 
anti- inflammatory (resolution) phenotype. Although understanding 
neutrophil resolution in the context of cerebrovascular inflammation 
has resulted in promising pre- clinical studies, further investigation 
is necessary to unravel the pathophysiological responses contribut-
ing to neurovascular thrombo- inflammation. More specifically, the 
potential use of endogenous biosynthetic circuits (such as Annexin 
A1/FPR- 2 pathway) may play a significant role in guiding therapies 
targeting the major players (such as neutrophils and platelets) on the 
thrombo- inflammatory stage.
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